These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33941060)

  • 1. DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol.
    Hernández-Guío A; Bernabéu-Martínez MªÁ; Corno-Caparrós A; Aznar-Saliente MªT; Bonete-Sánchez M; Calleja-Hernández MÁ
    Farm Hosp; 2021 Apr; 45(3):155-159. PubMed ID: 33941060
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Ikonnikova A; Fedorinov D; Gryadunov D; Heydarov R; Lyadova M; Moskalenko A; Mikhailovich V; Emelyanova M; Lyadov V
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
    Meulendijks D; Henricks LM; Sonke GS; Deenen MJ; Froehlich TK; Amstutz U; Largiadèr CR; Jennings BA; Marinaki AM; Sanderson JD; Kleibl Z; Kleiblova P; Schwab M; Zanger UM; Palles C; Tomlinson I; Gross E; van Kuilenburg AB; Punt CJ; Koopman M; Beijnen JH; Cats A; Schellens JH
    Lancet Oncol; 2015 Dec; 16(16):1639-50. PubMed ID: 26603945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Amstutz U; Froehlich TK; Largiadèr CR; Beijnen JH; de Boer A; Deenen MJ; Cats A; Schellens JH
    Int J Cancer; 2016 Jun; 138(11):2752-61. PubMed ID: 26804235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
    Lau DK; Fong C; Arouri F; Cortez L; Katifi H; Gonzalez-Exposito R; Razzaq MB; Li S; Macklin-Doherty A; Hernandez MA; Hubank M; Fribbens C; Watkins D; Rao S; Chau I; Cunningham D; Starling N
    BMC Cancer; 2023 Apr; 23(1):380. PubMed ID: 37101114
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Ragia G; Biziota E; Koukaki T; Amarantidis K; Manolopoulos VG
    Pharmacogenomics; 2024 Jan; 25(2):59-67. PubMed ID: 38353109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.
    Wigle TJ; Povitz BL; Medwid S; Teft WA; Legan RM; Lenehan J; Nevison S; Panuganty V; Keller D; Mailloux J; Siebring V; Sarma S; Choi YH; Welch S; Winquist E; Schwarz UI; Kim RB
    Clin Transl Sci; 2021 Jul; 14(4):1338-1348. PubMed ID: 33620159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity.
    Froehlich TK; Amstutz U; Aebi S; Joerger M; Largiadèr CR
    Int J Cancer; 2015 Feb; 136(3):730-9. PubMed ID: 24923815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
    Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Menghi M; Magnani M
    Br J Cancer; 2017 Oct; 117(9):1269-1277. PubMed ID: 29065426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
    Del Re M; Cinieri S; Michelucci A; Salvadori S; Loupakis F; Schirripa M; Cremolini C; Crucitta S; Barbara C; Di Leo A; Latiano TP; Pietrantonio F; Di Donato S; Simi P; Passardi A; De Braud F; Altavilla G; Zamagni C; Bordonaro R; Butera A; Maiello E; Pinto C; Falcone A; Mazzotti V; Morganti R; Danesi R
    Pharmacogenomics J; 2019 Dec; 19(6):556-563. PubMed ID: 30723313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
    Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
    Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
    Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
    Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; van Werkhoven E; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
    Eur J Cancer; 2019 Jan; 107():60-67. PubMed ID: 30544060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
    Toffoli G; Giodini L; Buonadonna A; Berretta M; De Paoli A; Scalone S; Miolo G; Mini E; Nobili S; Lonardi S; Pella N; Lo Re G; Montico M; Roncato R; Dreussi E; Gagno S; Cecchin E
    Int J Cancer; 2015 Dec; 137(12):2971-80. PubMed ID: 26099996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
    Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H
    Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis.
    Le Teuff G; Cozic N; Boyer JC; Boige V; Diasio RB; Taieb J; Meulendijks D; Palles C; Schwab M; Deenen M; Largiadèr CR; Marinaki A; Jennings BA; Wettergren Y; Di Paolo A; Gross E; Budai B; Ackland SP; van Kuilenburg ABP; McLeod HL; Milano G; Thomas F; Loriot MA; Kerr D; Schellens JHM; Laurent-Puig P; Shi Q; Pignon JP; Etienne-Grimaldi MC;
    Br J Cancer; 2024 Mar; 130(5):808-818. PubMed ID: 38225422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.
    Amstutz U; Offer SM; Sistonen J; Joerger M; Diasio RB; Largiadèr CR
    Clin Cancer Res; 2015 May; 21(9):2038-44. PubMed ID: 25655103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study.
    Miarons M; Manzaneque Gordón A; Riera P; Gutiérrez Nicolás F;
    Oncologist; 2023 May; 28(5):e304-e308. PubMed ID: 37014829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
    Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
    Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.